hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06383767, orgStudyIdInfo id: ESG401-301, briefTitle: A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-30, primaryCompletionDateStruct date: 2026-07-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Shanghai Escugen Biotechnology Co., Ltd, class: INDUSTRY, descriptionModule briefSummary: The aim of this study is to evaluate the efficacy and safety of ESG401 in patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer., conditionsModule conditions: Metastatic Breast Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 378, type: ESTIMATED, armsInterventionsModule interventions name: ESG401, interventions name: Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice), outcomesModule primaryOutcomes measure: Progression-free survival (PFS) assessed by IRC per RECIST 1.1, secondaryOutcomes measure: Progression-free survival (PFS) assessed by the investigators per RECIST V 1.1, secondaryOutcomes measure: Overall Survival (OS), secondaryOutcomes measure: Objective Response Rate (ORR), secondaryOutcomes measure: Clinical Benefit Rate (CBR), secondaryOutcomes measure: Duration of Response (DoR), secondaryOutcomes measure: Quality of life evaluated using the NCC-BC-A scale, secondaryOutcomes measure: Adverse events(AEs) and severe adverse events (SAEs), secondaryOutcomes measure: Clearance, secondaryOutcomes measure: Volume of distribution, secondaryOutcomes measure: ADA, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Cancer Hospital Chinese Academy of Medical Sciences, city: Beijing, state: Beijing, zip: 100021, country: China, contacts name: Fei Ma, PhD, role: CONTACT, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06383754, orgStudyIdInfo id: Clove, briefTitle: Clareon Intraocular Lens Stability in Vitrectomy Patients: CLOVE Study, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-06-07, primaryCompletionDateStruct date: 2024-03-08, completionDateStruct date: 2024-03-15, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: The University of Hong Kong, class: OTHER, descriptionModule briefSummary: This prospective randomized controlled trial will be conducted to investigate Clareon intraocular lens (IOL) stability in vitrectomy patients. The investigator plans to target the patients undergoing cataract surgery. A randomized study will be conducted with 2 arms, one with Clareon IOL versus a second arm using the Tecnis 1 In this non-inferiority study, the investigator will compare Clareon IOL from Alcon with the existing Tecnis 1 IOL from Precision Lens which is the commonly used intraocular lens in combined vitrectomy cases in Hong Kong., conditionsModule conditions: Senile Cataract, conditions: Epiretinal Membrane, conditions: Vitreous Hemorrhage, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: Patients are randomised and masked from the treatment, whoMasked: PARTICIPANT, enrollmentInfo count: 50, type: ACTUAL, armsInterventionsModule interventions name: Clareon, interventions name: Tecnis 1, outcomesModule primaryOutcomes measure: Position stability of Clareon and Tecnis 1 IOL, secondaryOutcomes measure: Visual acuity, secondaryOutcomes measure: Refraction, secondaryOutcomes measure: Axial movement, secondaryOutcomes measure: Decentration, secondaryOutcomes measure: Compare intra operative and post operative complication, eligibilityModule sex: ALL, minimumAge: 50 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Grantham Hospital, city: Hong Kong, country: Hong Kong, geoPoint lat: 22.27832, lon: 114.17469, hasResults: False
protocolSection identificationModule nctId: NCT06383728, orgStudyIdInfo id: ES-2024-014-02, briefTitle: Osimertinib as Neoadjuvant Therapy in Patients With Resectable Stage II-IIIB EGFR-mutated Lung Squamous Cell Carcinoma, acronym: GALAXY-02, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-10-31, completionDateStruct date: 2029-04-30, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: The First Affiliated Hospital of Guangzhou Medical University, class: OTHER, descriptionModule briefSummary: Previous trials, such as ADURA and CTONG, have demonstrated the benefits of neoadjuvant targeted therapy in patient with EGFR mutations, which can effectively reduce the extent of tumors and improve the survival outcomes. However, clinical trials of neoadjuvant targeted therapy in NSCLC have rarely enrolled patients with EGFR-mutated lung squamous cell carcinoma due to its rarity, which means that the safety and feasibility of neoadjuvant osimertinib in patients with resectable stage II-IIIB EGFR-mutated lung squamous cell carcinoma remains relatively unknown., conditionsModule conditions: Lung Cancer, conditions: Carcinoma, Squamous Cell, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Patients with resectable stage II-IIIB EGFR-mutated lung squamous cell carcinoma receive osimertinib (80mg/d, ≥9 weeks), primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 51, type: ESTIMATED, armsInterventionsModule interventions name: Osimertinib, outcomesModule primaryOutcomes measure: Objective Response Rate, ORR, primaryOutcomes measure: Safety: frequency of severe adverse events, secondaryOutcomes measure: Major pathologic response, MPR, secondaryOutcomes measure: R0 rate, secondaryOutcomes measure: Progression-free survival (PFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Disease control rate (DCR), secondaryOutcomes measure: Duration of remission (DOR), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital of Guangzhou Medical University, status: RECRUITING, city: Guangzhou, state: Guangdong, zip: 510120, country: China, contacts name: Shuben Li, Doctor, role: CONTACT, email: 13500030280@163.com, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06383715, orgStudyIdInfo id: 2024-624, briefTitle: Congitive Behavioral Therapy Workshop for Content Moderators, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-08-01, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Universidad Europea de Valencia, class: OTHER, descriptionModule briefSummary: Professional content moderators play a critical role in preventing Internet users from being exposed to more sensitive content. However, recent literature has shown that this work places content moderators at increased risk for several psychological outcomes, including intrusive thoughts and vicarious stress trauma. This pilot study will assess the acceptability and feasibility of a brief (4-session) cognitive-behavioral workshop to reduce these risks., conditionsModule conditions: Work-Related Condition, conditions: Work-Related Stress Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: Cognitive-Behavioral Therapy Workshop for Content Moderators, outcomesModule primaryOutcomes measure: The Kessler Psychological Distress Scale (K10), secondaryOutcomes measure: Work Satisfaction Scale, JobStat'73, secondaryOutcomes measure: Coping Mechanisms Scale, secondaryOutcomes measure: PTSD Checklist-Civilian Version (PCL-C), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: MEGA cloud services, status: RECRUITING, city: Salamanca, zip: 37002, country: Spain, contacts name: Valentina Sirna, role: CONTACT, phone: +34 685 34 79 07, email: support@mega.nz, contacts name: Carlos López-Pinar, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 40.96882, lon: -5.66388, hasResults: False
protocolSection identificationModule nctId: NCT06383702, orgStudyIdInfo id: HEX1939-002, briefTitle: Phase III Trial to Evaluate the Efficacy and Safety of Pregabalin in the Treatment of Painful Diabetic Peripheral Neuropathy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-15, primaryCompletionDateStruct date: 2025-04-01, completionDateStruct date: 2025-04-15, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: CSPC Ouyi Pharmaceutical Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: This study is designed to evaluate the efficacy and safety of pregabalin extended-release tablets in the treatment of neuropathic pain associated with diabetic peripheral neuropathy. Pregabalin has been approved in more than 130 countries for neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and neuralgia associated with spinal cord injury. Pregabalin extended-release tablets were administered once daily, as a single dose after dinner. Compared with pregabalin capsule formulation, it reduces the frequency of medication and improves patient compliance., conditionsModule conditions: Neuropathic Pain Associated With Diabetic Peripheral Neuropathy, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Parallel design, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 358, type: ESTIMATED, armsInterventionsModule interventions name: pregabalin sustained-release tablets, interventions name: Placebo, outcomesModule primaryOutcomes measure: NRS mean change at week 13, secondaryOutcomes measure: NRS mean change at Weeks 1-12 and 14, secondaryOutcomes measure: Proportion of subjects with NRS reduction, secondaryOutcomes measure: MOS-SS score, secondaryOutcomes measure: HADS score, secondaryOutcomes measure: PGIC score, secondaryOutcomes measure: CGIC score, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06383676, orgStudyIdInfo id: 1, briefTitle: Effect Of Functional Balance Exercise İn Elderly, acronym: RCT, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-04-20, primaryCompletionDateStruct date: 2024-11-30, completionDateStruct date: 2025-05-30, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Tarsus University, class: OTHER, descriptionModule briefSummary: The elderly population is increasing in Turkey and in the world. Many health problems, such as a decrease in physical and psychological abilities and an increase in chronic problems, occur with aging. It is important to encourage and support practices for the development of exercises to increase physical and cognitive capacity in order to early recognize and reduce the effects of problems that develop with aging. To the best of our knowledge, there is no exercise training to increase reaction time in the elderly in the literature., conditionsModule conditions: Older People, conditions: Exercise, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: The study was planned as a randomized controlled study, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: Study participants are unaware of their assigned group, whoMasked: PARTICIPANT, enrollmentInfo count: 28, type: ACTUAL, armsInterventionsModule interventions name: Functional reaction balance training, interventions name: Functional balance training, outcomesModule primaryOutcomes measure: The Montreal Cognitive Assessment (MoCA), primaryOutcomes measure: Stroop Test, primaryOutcomes measure: The Simple Reaction Time, secondaryOutcomes measure: The Four Square Step Test (FSST), secondaryOutcomes measure: The short physical performance battery (SPPB), secondaryOutcomes measure: Timed Up and Go Test (TUG), secondaryOutcomes measure: Falls Efficacy Scale ( FES), secondaryOutcomes measure: Mini-BESTest: Balance Evaluation Systems Test, eligibilityModule sex: ALL, minimumAge: 65 Years, maximumAge: 85 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fatma Kübra ÇEKOK, city: Ankara, zip: 06000, country: Turkey, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False
protocolSection identificationModule nctId: NCT06383663, orgStudyIdInfo id: 308-2019-04-01, briefTitle: A RCT of Supraclavicular Lymph Node Dissection vs. No-dissection in Supraclavicular Lymph Node Metastatic Breast Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2028-12-31, completionDateStruct date: 2029-12-31, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Sun Yat-sen University, class: OTHER, descriptionModule briefSummary: The purpose of this study was to compare the efficacy of surgical dissection of supraclavicular lymph nodes combined with radiotherapy versus radiotherapy alone in patients with ipsilateral supraclavicular lymph node metastasis., conditionsModule conditions: Breast Cancer, conditions: Ipsilateral Supraclavicular Lymph Node Metastasis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Supraclavicular lymph node dissection combined with radiotherapy versus radiotherapy alone, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 452, type: ESTIMATED, armsInterventionsModule interventions name: Supraclavicular lymph node dissection combined with radiotherapy, interventions name: radiotherapy, outcomesModule primaryOutcomes measure: DFS, secondaryOutcomes measure: PFS, secondaryOutcomes measure: OS, otherOutcomes measure: pCR rate, eligibilityModule sex: FEMALE, minimumAge: 35 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06383650, orgStudyIdInfo id: 124532, briefTitle: Use of 81 vs 325mg of ASA in Treatment of BCVI, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2025-05, completionDateStruct date: 2025-09, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: London Health Sciences Centre, class: OTHER, collaborators name: Western University, descriptionModule briefSummary: Blunt cerebrovascular injury (BCVI), or injury to the carotid and vertebral arteries, occurs in 1-3% of blunt traumas, often as a result of injury to the head, neck, or chest. If unrecognized or untreated, BCVI can lead to stroke, which occurs in approximately 20% of untreated patients, potentially causing significant and sometimes permanent disability. Early diagnosis and treatment significantly reduce the risk of stroke.Currently, there is wide variation across centers and trauma care providers in treatment strategies for BCVI and the most recent guidelines are unable to make specific recommendations about the optimal agent and/or dose of treatment to reduce the risk of stroke after BCVI while minimizing bleeding complications in patients with multiple traumatic injuries. Recent systematic reviews and meta-analyses evaluating the most common treatment strategies for BCVI have shown similar stroke rates with the use of anticoagulants (usually heparin) vs. antiplatelets (usually aspirin/ASA), however, treatment with antiplatelets was associated with a lower risk of bleeding complications. The optimal dose of ASA for stroke prevention while minimizing bleeding complications is unknown, and more research is required to inform future care.This project will investigate two doses of antiplatelet therapy (81 mg daily vs. 325 mg daily aspirin) for BCVI treatment, and will look at the risk of stroke and bleeding complications with each strategy. The goal of the research is to determine whether a large-scale study looking at this question is feasible, which will ultimately help determine the best medical therapy for patients with BCVI., conditionsModule conditions: Carotid Artery Injuries, conditions: Traumatic Injury, conditions: Vertebral Artery Injury, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Acetylsalicylic Acid, outcomesModule primaryOutcomes measure: Study feasibility, secondaryOutcomes measure: Incidence of stroke, secondaryOutcomes measure: Incidence of Bleeding Complications, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06383637, orgStudyIdInfo id: KAP-ABR-Interns, briefTitle: Antibiotic Use and Resistance KAP Among Dental Interns, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2024-11-01, completionDateStruct date: 2024-12-01, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: The study is designed as a cross-sectional online-based questionnaire, and it will be distributed among dental interns. Assess the following among dental interns (1) The knowledge, attitude, and practices (KAP) towards antibiotics and antibiotic resistance; (2) The correlation between their KAP score and where they spend their internship year? (4) Development of the curriculum to provide sufficient training and information about antibiotics and antibiotic resistance., conditionsModule conditions: Antibiotic Side Effect, conditions: Antibiotic Resistant Infection, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 343, type: ESTIMATED, outcomesModule primaryOutcomes measure: Knowledge of dental interns regarding antibiotic use and resistance, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06383624, orgStudyIdInfo id: RC18-4-2023, briefTitle: Impact Of Maternal Spinal Anesthesia-Induced Hypotension At Scheduled Cesarean Delivery On Risk Development Of Transient Tachypnea Of Newborn And Fetal Acidosis, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-04-01, primaryCompletionDateStruct date: 2024-03-01, completionDateStruct date: 2024-03-31, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Benha University, class: OTHER, descriptionModule briefSummary: We will evaluate the association between transient tachypnea of newborns and fetal acidosis development to the degree and duration of maternal hypotension and anesthesia to delivery time during spinal anesthesia at scheduled cesarean delivery., conditionsModule conditions: Transient Tachypnea of Newborn and Fetal Acidosis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CROSSOVER, timePerspective: PROSPECTIVE, enrollmentInfo count: 115, type: ACTUAL, outcomesModule primaryOutcomes measure: Association between transient tachypnea of newborns development to the degree and duration of maternal hypotension during spinal anesthesia at scheduled cesarean delivery, primaryOutcomes measure: Association between fetal acidosis development to the degree and duration of maternal hypotension and anesthesia to delivery time during spinal anesthesia at scheduled cesarean delivery, eligibilityModule sex: ALL, minimumAge: 1 Minute, maximumAge: 6 Hours, stdAges: CHILD, contactsLocationsModule locations facility: Benha University Hospital, city: Cairo, zip: 13511, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06383611, orgStudyIdInfo id: OTX-0303, briefTitle: Expanded Access to Cyclic Irrigation in Patients Undergoing Exchange Arthroplasty, acronym: APEX-EAP, statusModule overallStatus: AVAILABLE, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Osteal Therapeutics, Inc., class: INDUSTRY, descriptionModule briefSummary: The objective of the protocol is to provide access to the VT-X7 (Vancomycin, Tobramycin Exchanged in 7 Days) system for subjects with periprosthetic joint infection (PJI) of the hip or knee who lack therapeutic treatment alternatives., conditionsModule conditions: Prosthetic-joint Infection, designModule studyType: EXPANDED_ACCESS, armsInterventionsModule interventions name: VT-X7 Treatment System, eligibilityModule sex: ALL, minimumAge: 22 Years, maximumAge: 84 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06383598, orgStudyIdInfo id: 2022KT74-ZY01, briefTitle: PD-L1 Specific [68Ga]-Nb-1 Nanobody Probe for PET Imaging in Solid Tumors, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-05-09, primaryCompletionDateStruct date: 2026-12, completionDateStruct date: 2026-12, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Peking University Cancer Hospital & Institute, class: OTHER, descriptionModule briefSummary: The objective of the study is to constrcut a noninvasive approach 68Ga-Nb-1 PET/CT to detect the PD-L1 expression of tumor lesions in patients with solid tumors and to identify patients benefiting from anti-PD-L1 treatment., conditionsModule conditions: Solid Tumor, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: 18F-FDG, outcomesModule primaryOutcomes measure: Standardized uptake value（SUV）, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Beijing Cancer Hospital, status: RECRUITING, city: Beijing, state: Beijing, zip: 100142, country: China, contacts name: Hua Zhu, role: CONTACT, phone: +861088196495, email: zhuhuananjing@163.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False